Treatment of ChronicMyelomonocytic Leukemia with 5-Azacytidine: Case Reports
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F12%3A33142581" target="_blank" >RIV/61989592:15110/12:33142581 - isvavai.cz</a>
Result on the web
<a href="http://www.hindawi.com/crim/hematology/2012/369086/" target="_blank" >http://www.hindawi.com/crim/hematology/2012/369086/</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1155/2012/369086" target="_blank" >10.1155/2012/369086</a>
Alternative languages
Result language
angličtina
Original language name
Treatment of ChronicMyelomonocytic Leukemia with 5-Azacytidine: Case Reports
Original language description
Epigenetic therapy with hypomethylating agent (5-azacytidine; AZA) is common in the management of specific subtypes of myelodysplastic syndrome (MDS), but there are only few studies in chronic myelomonocytic leukemia (CMML) patients. In this paper our experience with 3 CMML patients treated with AZA is described. In one patient transfusion independency was observed after 4 treatment cycles; in one case a partial response was recorded, but a progression to acute myeloid leukemia (AML) after 13 AZA cycleshas appeared. In one patient, AZA in reduced dosage was administered as a bridging treatment before allogeneic stem cell transplantation (ASCT), but in the control bone marrow aspirate (before ASCT) a progression to AML was recorded. Future studies aremandatory for evaluation of new molecular and clinical features which could predict the efficiency of hypomethylating agents in CMML therapy with respect to overall survival, event-free survival, quality-adjusted life year, and pharmacoec
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/NT12218" target="_blank" >NT12218: Personalized treatment of chronic myeloproliferative disorders and myelodysplastic syndrome - a cellular metabolomics study.</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)<br>S - Specificky vyzkum na vysokych skolach
Others
Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Case Reports in Hematology
ISSN
2090-6579
e-ISSN
—
Volume of the periodical
2012
Issue of the periodical within the volume
369086
Country of publishing house
US - UNITED STATES
Number of pages
4
Pages from-to
1-4
UT code for WoS article
—
EID of the result in the Scopus database
—